Power3 to focus breast cancer tests on blood serum

New York, March 27 - Power3 Medical Products, Inc. said it plans to focus its development work on early-stage tests for breast cancer on blood serum.

The decision follows trials including studies with breast nipple aspirate fluid under a patent licensed from a major cancer center.

"In our clinical validation studies, women constantly complained that the breast nipple aspiration was even more painful than a mammogram," said Steven B. Rash, chairman and chief executive officer of Power3, in a news release.

"Another problem was that the success rate in getting samples was less than 50% . . . and even when samples were successfully drawn, they were often not representative enough for accurate testing."

Power3 noted it has successfully used blood serum as the platform for its NuroPro neurodegenerative tests, with more than 650 patient and control samples.

Power3 is a Houston-based proteomics company that develops and commercializes early detection diagnostic tests for cancer and neurodegenerative diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.